(P133) Variation in Insurance Status by Patient Demographics and Tumor Site Among the Top Twenty-Five Causes of Cancer

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

In the United States, an estimated 48 million individuals live without health insurance. The purpose of this study is to explore differences in key factors associated with insurance status among non-Medicare-aged adults diagnosed with the top 25 incident cancers using the Surveillance, Epidemiology, and End Results (SEER) public-use database.

Stephen R. Grant, BS, Gary V. Walker, MD, MPH, Ashleigh Guadagnolo, MD, MPH, Matthew Koshy, MD, Usama Mahmood, MD; UT MD Anderson Cancer Center

Background: In the United States, an estimated 48 million individuals live without health insurance. The purpose of this study is to explore differences in key factors associated with insurance status among non-Medicare-aged adults diagnosed with the top 25 incident cancers using the Surveillance, Epidemiology, and End Results (SEER) public-use database.

Methods: A total of 688,794 patients aged 18-64 years diagnosed with 1 of the top 25 incident cancers (representing 95% of all cancer diagnoses) between 2007 and 2010 in the SEER database were analyzed. Patient characteristics included age, race, gender, marital status, rural residence, and tumor stage. County-level demographics included percent poverty level. Insurance status was defined as insured, Medicaid, or uninsured. A multivariate logistic regression model was used to determine factors associated with lack of insurance.

Results: Of the 688,794 eligible patients, 536,297 (77.9%) had insurance, 76,516 (11.1%) had Medicaid, and 33,798 (4.9%) did not have insurance. On univariate analysis, the following demographic characteristics were associated with lack of insurance: younger age, male gender, nonwhite race, being unmarried, rural residence, and residing in a county with higher poverty level (all P < .0001). The cancer types with the highest rates of insurance coverage were prostate cancer (92.3%), melanoma of the skin (92.5%), and thyroid cancer (89.5%). The lowest rates of insurance were seen among patients with cancer of the cervix (64.2%), liver (67.9%), and stomach (70.9%). Among those uninsured, the top three causes of cancer were lung cancer (14.9%), colorectal cancer (12.1%), and breast cancer (10.2%). Among those with Medicaid, the top three causes of cancer were breast cancer (21.3%), lung cancer (15.7%), and colorectal cancer (9.2%). Males were more likely to be uninsured (5.8% vs 4.7%), and females were more likely to have Medicaid (13.3% vs 10.2%) (P < .0001). Insurance rates increased with age and ranged from 73.6% for 18–29-year-olds to 85.8% for 60–64-year-olds (P < .0001). Nonwhite individuals represented 45.5% of the uninsured vs only 26.9% of the insured (P < .0001). The rate of insurance decreased from 84.1% in 2007 to 81.5% in 2010 (P < .0001). In a multivariate logistic regression, younger age, female gender, nonwhite race, being unmarried, rural residence, and residence in a county with a higher percent below poverty were associated with the lack of insurance.

Conclusions: Large disparities exist in the rates of insurance by cancer type. Younger age, female gender, nonwhite race, being unmarried, rural residence, and residence in a county with a higher percent below poverty were associated with lack of insurance. The expansion of private insurance would be expected to disproportionally benefit certain populations and cancer types.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
Related Content